The stock of Flexion Therapeutics Inc (NASDAQ:FLXN) hit a new 52-week high and has $28.60 target or 33.00% above today’s $21.50 share price. The 5 months bullish chart indicates low risk for the $643.40M company. The 1-year high was reported on Nov, 11 by Barchart.com. If the $28.60 price target is reached, the company will be worth $212.32M more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock. About 335,985 shares traded hands or 29.28% up from the average. Flexion Therapeutics Inc (NASDAQ:FLXN) has risen 83.63% since April 11, 2016 and is uptrending. It has outperformed by 77.48% the S&P500.
Analysts await Flexion Therapeutics Inc (NASDAQ:FLXN) to report earnings on November, 14. They expect $-0.67 EPS, down 28.85% or $0.15 from last year’s $-0.52 per share. After $-0.63 actual EPS reported by Flexion Therapeutics Inc for the previous quarter, Wall Street now forecasts 6.35% negative EPS growth.
Flexion Therapeutics Inc (NASDAQ:FLXN) Ratings Coverage
Out of 7 analysts covering Flexion Therapeutics (NASDAQ:FLXN), 7 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Flexion Therapeutics has been the topic of 7 analyst reports since July 31, 2015 according to StockzIntelligence Inc. The stock of Flexion Therapeutics Inc (NASDAQ:FLXN) earned “Buy” rating by Lake Street on Thursday, July 21. The stock of Flexion Therapeutics Inc (NASDAQ:FLXN) earned “Outperform” rating by BMO Capital Markets on Wednesday, June 29. The company was initiated on Wednesday, November 4 by Cantor Fitzgerald. The stock has “Buy” rating given by Needham on Wednesday, September 9. The firm has “Outperform” rating given on Tuesday, May 3 by Wells Fargo.
According to Zacks Investment Research, “Flexion Therapeutics, Inc. is a specialty pharmaceutical company. It is focused on the development and commercialization of injectable pain therapies. The Company is targeting anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It operates in the United States. The Company’s product candidate, FX006, is an injectable intra-articular, meaning in the joint, sustained-release treatment for patients with moderate to severe OA pain. It is developing two additional product candidates, FX007 for post-operative pain and FX005 to treat end-stage OA patients. Flexion Therapeutics, Inc. is headquartered in Burlington, Massachusetts.”
Insitutional Activity: The institutional sentiment increased to 2.85 in Q2 2016. Its up 1.20, from 1.65 in 2016Q1. The ratio improved, as 9 funds sold all Flexion Therapeutics Inc shares owned while 11 reduced positions. 21 funds bought stakes while 36 increased positions. They now own 18.68 million shares or 38.37% more from 13.50 million shares in 2016Q1.
California State Teachers Retirement System, a California-based fund reported 38,813 shares. Deutsche Bancorp Ag accumulated 0% or 14,461 shares. Oxford Asset has 209,593 shares for 0.13% of their US portfolio. Morgan Stanley holds 0% of its portfolio in Flexion Therapeutics Inc (NASDAQ:FLXN) for 25,957 shares. Tower Research Capital Ltd Limited Liability Company (Trc) last reported 0% of its portfolio in the stock. Dupont Management, a Delaware-based fund reported 19,491 shares. Geode Capital Mngmt Limited Liability Company has 145,396 shares for 0% of their US portfolio. Alliancebernstein Lp last reported 0% of its portfolio in the stock. Wall Street Associate last reported 113,400 shares in the company. Blackrock, a New York-based fund reported 2,018 shares. Jacobs Levy Equity has invested 0.01% of its portfolio in Flexion Therapeutics Inc (NASDAQ:FLXN). Sabby Mngmt Lc last reported 0.08% of its portfolio in the stock. Goldman Sachs Group Inc Inc, a New York-based fund reported 20,859 shares. Teachers Retirement System Of The State Of Kentucky owns 28,040 shares or 0.01% of their US portfolio. The Illinois-based Ubs Oconnor Limited Liability Company has invested 0% in Flexion Therapeutics Inc (NASDAQ:FLXN).
Insider Transactions: Since May 16, 2016, the stock had 15 buys, and 0 selling transactions for $30.21 million net activity. Versant Ventures III – LLC bought $10.00 million worth of Flexion Therapeutics Inc (NASDAQ:FLXN) on Wednesday, June 8. 2,500 Flexion Therapeutics Inc (NASDAQ:FLXN) shares with value of $22,972 were bought by DRISCOLL FREDERICK W. On Wednesday, June 8 LUBASH BARBARA N bought $10.00 million worth of the stock or 714,285 shares. Another trade for 2,000 shares valued at $20,465 was made by Clayman Michael D. on Wednesday, May 18. $13,387 worth of shares were bought by MERRIFIELD C ANN on Tuesday, June 14. The insider Bodick Neil bought $11,525. COLELLA SAMUEL D had bought 714,285 shares worth $10.00M on Wednesday, June 8.
More news for Flexion Therapeutics Inc (NASDAQ:FLXN) were recently published by: Streetinsider.com, which released: “Flexion Therapeutics (FLXN) Announces Presentation of Statistically …” on November 11, 2016. Marketwatch.com‘s article titled: “/quotes/zigman/3870025/realtime” and published on February 13, 2014 is yet another important article.
FLXN Company Profile
Flexion Therapeutics, Inc., incorporated on November 5, 2007, is a specialty pharmaceutical company. The Firm is focused on the development and commercialization of therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis and post-operative pain. The Company’s portfolio of product candidates addresses the OA pain treatment spectrum, from moderate to severe pain. The Company’s lead product candidate, Zilretta (also known as FX006), is a late-stage, injectable, sustained-release, intra-articular (IA) steroid for patients with moderate to severe OA pain. The Company’s other product candidates include FX007 for post-operative pain and FX005 for the treatment of end-stage OA patients. The Firm has not generated any revenue.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.